Excerpts

In terms of the therapeutic dose, an increasing trend with treatment duration was observed in the included studies.

Poly (I:C) may have indirectly activated STAT3 signaling and switched on the IL6 amplifier, leading to the further activation of IL6 release While we observed background Tyr-705 phosphorylated STAT3 (p-STAT3) in untreated cells [(-)-WD-(-)], the activation of STAT3 in MRC-5 lung fibroblasts treated with PolyIC–WD–TNF showed a trend which was slightly higher than that of cells treated with (-)-WD–TNF at all the time points examined.

Conversely, the expression of CD86 and CD83 showed an elevated trend.

There was a marked trend towards lower expression of HLA-DR and HLA-A, B, and C on mDCs and pDCs of MM patients compared to HDs ( 41 ).

We showed a trend in monocyte frequency before starting treatment with baricitinib, with lower levels in R patients compared with NR (not significant).

At 5.5 months after primary vaccination, the neutralizing activity correlated weakly with IgM/G titers; however, after the ‘booster’ (7 months after primary vaccination), the correlation was highly significant for all variants, indicating that induction of high titers is associated with potent neutralization ( Figure 2D , r ≥ 0.73, Spearman).

BMI showed a decreasing trend among subtypes in the following order: II, I, III, IV ( Figure 4F ).

Meanwhile, triglycerides (TGs) showed an increasing trend among subtypes in the following order: II, I, III, IV ( Figure 4M ).

Compared with the control group, adenosine combined with other nucleosides had extremely significant inhibitory effects on TNF-α ( Figures 9E ) and IL-6 ( Figure 9F ).

AZA, MMF, OC and RTX showed a trend to decrease ARR, but those results did not reach significant differences.

The comparison of paired samples divided into drug groups revealed that CCL4, as already detected in the Olink, was the protein which increased most post-PrEP, followed by two additional proteins CXCL10 and MCP-1, which were also among the highly significant proteins detected in Olink ( Figure 2 ).

The inhaled pan-JAK inhibitor nezulcitinib (TD-0903, Theravance Biopharma) was used for treatment of COVID-19 associated lung injury in a Phase II clinical trial ( NCT04402866 ) but failed to meet its primary endpoint; however, the drug was well-tolerated and showed a trend towards decreased mortality and duration of hospitalization ( 192 ).

Overall, our findings suggest that the oral microbiota of HRIS and IS are more diverse than that of HC and show an increasing trend.

This revealed a significantly larger number of EBV-specific TCRs in MS patients compared to healthy controls while none of the other infectious TCRs had a notable trend.

According to statistics, the global incidence of NAFLD is about 25% ( 1 ), and the prevalence in China is about 29.2% ( 2 ), accompanied by an increasing trend of younger age ( 3 ).

In the placebo group, the %FVC and %DLco values showed a decreasing trend but no significant worsening over the course of 1 year.

This trial had a high proportion of patients with mild SSc-associated interstitial lung disease, but a subanalysis of only patients with baseline %FVC less than 80% also showed a trend toward better %FVC in the rituximab group than in the placebo group.

Second, the subtypes distribution of JIA may be significant among the different ethnic groups.

Toll-like receptor 6 ( TLR6 ) showed a trend towards higher expression in intM and ncM.

Staphylococci, Peptoniphilus , and Finegoldia -related ASVs showed a trend towards higher prevalence in AN of patients than in the MM.

Concordant with the results obtained for overall and high-level CMV infection, carriers of the G allele of TLR9 (rs5743836) in the homozygous or heterozygous state showed a trend toward a lower disease-free survival than homozygous carriers of the reference A allele (one-year survival rates: 83.2% versus 90.8%, respectively; log-rank test P -value = 0.149).

First, we have found that the presence in a homozygous state of the alternative allele of TLR3 (rs3775291) (TT genotype) exerts a protective role on the risk of CMV viremia at any level and, with borderline significance, at high-level (≥1,000 IU/ml) infection.

Although acalabrutinib-treated patients also showed a trend in reduced Treg to CD4+ ratio compared to baseline, these differences were not significant ( 108 ).

MHC class I was significantly reduced on macrophages derived from COPD patients, while MHC class II molecules only showed a trend towards lower expression.

A weak trend towards increased mast cell CPA3 protein was observed for small airways ( Figure 3B ).